ICH E2E Pharmacovigilance Planning

Target entity: ICH E2E Pharmacovigilance Planning
Context triple: [ICH E2D, relatedTo, ICH E2E Pharmacovigilance Planning]

• A. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• B. ICH E2A Clinical Safety Data Management
  ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
• C. Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs
  Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs (ICH E2C) is an international guideline that standardizes the format, content, and timing of periodic safety reports submitted by marketing authorization holders to monitor and communicate the ongoing safety profile of approved medicines.
• D. International Council for Harmonisation guideline E2C
  International Council for Harmonisation guideline E2C is a regulatory framework that provides standardized requirements for the ongoing safety evaluation and periodic benefit-risk assessment of marketed medicinal products.
• E. Centre for Pharmacovigilance
  The Centre for Pharmacovigilance is a Norwegian public health unit responsible for monitoring, assessing, and improving the safety of medicines and vaccines in Norway.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: ICH E2E Pharmacovigilance Planning
Target entity description: ICH E2E Pharmacovigilance Planning is an International Council for Harmonisation guideline that provides a structured framework for proactively planning and managing drug safety surveillance throughout a product’s life cycle.

• A. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• B. ICH E2A Clinical Safety Data Management
  ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
• C. Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs
  Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs (ICH E2C) is an international guideline that standardizes the format, content, and timing of periodic safety reports submitted by marketing authorization holders to monitor and communicate the ongoing safety profile of approved medicines.
• D. International Council for Harmonisation guideline E2C
  International Council for Harmonisation guideline E2C is a regulatory framework that provides standardized requirements for the ongoing safety evaluation and periodic benefit-risk assessment of marketed medicinal products.
• E. Centre for Pharmacovigilance
  The Centre for Pharmacovigilance is a Norwegian public health unit responsible for monitoring, assessing, and improving the safety of medicines and vaccines in Norway.
• F. None of above. chosen